Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

As SARS-CoV-2 continues to spread and evolve, detecting emerging variants early is critical
for public health interventions. Inferring lineage prevalence by clinical testing is infeasible at …

Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity
against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated …

We report on the sequencing of 74,348 SARS-CoV-2 positive samples collected across the
United States and show that the Delta variant, first detected in the United States in March …

Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform.
Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of …

Since its emergence in late 2019, the diffusion of SARS-CoV-2 is associated with the
evolution of its viral genome. The co-occurrence of specific amino acid changes, collectively …

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected almost 200
million people worldwide by July 2021 and the pandemic has been characterized by …

Abstract Objectives High‐magnitude CD8+ T cell responses are associated with mild COVID‐
19 disease; however, the underlying characteristics that define CD8+ T cell‐mediated …

Since the outbreak of the COVID-19 pandemic, many research organizations have studied
the genome of the SARS-CoV-2 virus; a body of public resources have been published for …

We report the complete genome sequence of a severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) Omicron variant (lineage B. 1.1. 529) from a Belgian patient …